Clinical trials: Ivonescimab
Pancreatic Cancer
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic…
- Trial name
- NCT06953999
- Testing
- Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 999 people
- Sponsor
- Akeso
Squamous Cell Lung Cancer
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin/carboplatin) in combination with Ivonescimab as first-line treatment…
- Trial name
- NCT07009925
- Testing
- Ivonescimab 20mg/kg intravenous every 3 weeks
- Volunteers
- 38 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Non-Squamous Non-small Cell Lung Cancer
Phase III Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT06396065
- Testing
- AK112 Injection
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 420 people
- Sponsor
- Summit Therapeutics
II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer, Perioperative
Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
This study is a prospective, II Phase clinical trial designed to evaluate the efficacy and safety of ivonescimab as monotherapy or in combination with platinum-based chemotherapy in the perioperative treatment of resectable…
- Trial name
- NCT07241819
- Testing
- Ivonescimab/surgery, Ivonescimab/chemotherapy/surgery
- Volunteers
- 66 people
- Sponsor
- Peking University Cancer Hospital & Institute
SCLC
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.
- Trial name
- NCT06820762
- Testing
- irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Stomach Cancer Stage IV, Esophagus Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
- Conditions
- Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
- Trial name
- NCT07070466
- Testing
- Ivonescimab, 5-Fluorouracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Esophageal Squamous Cell Carcinoma, Ivonescimab
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
- Trial name
- NCT07385001
- Testing
- AK112, AK112 + Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tang-Du Hospital
Small Cell Lung Cancer
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed…
- Trial name
- AK112-311 (NCT07010263)
- Testing
- AK112
- Where
- 53 sites in China
- Volunteers
- 560 people
- Sponsor
- Akeso
Colon Cancer
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Neoadjuvant chemotherapy has been validated by several clinical studies to achieve preoperative downstaging and improve survival outcomes in patients with locally advanced colon cancer .
- Trial name
- NCT06790212
- Testing
- Ivonescimab, Oxaliplatin, Capecitabine
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Thymus Carcinoma
Ivonescimab for the Treatment of Thymic Cancer
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may…
- Trial name
- NCT06980077
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
This is a randomized, open-label, active-comparator-controlled, multi-regional, three-arm, phase 3 study comparing the efficacy and safety of ivonescimab in combination with ligufalimab to pembrolizumab and of ivonescimab alone…
- Trial name
- ILLUMINE (NCT07264075)
- Testing
- Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®)
- Where
- France
- Volunteers
- 780 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
- Trial name
- NCT06567314
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small-cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line…
- Trial name
- NCT06478043
- Testing
- ivonescimab, irinotecan liposome
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Esophagus Cancer
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
As a humanized bispecific antibody targeting PD-1 and VEGF-A, everolizumab exhibits high specificity for binding PD-1 and VEGF-A in vivo.
- Trial name
- NCT07440212
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Nasopharyngeal Carcinoma (NPC)
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune…
- Trial name
- AK112 (NCT07565389)
- Testing
- Ivonescimab 20 mg/kg
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- National University Hospital, Singapore
Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
To learn if the drug combination of tiragolumab and ivonescimab can help to control LSCC that got worse after standard treatment with platinum doublets and anti-PD-1/PD-L1 therapy.
- Trial name
- NCT07038915
- Testing
- Tiragolumab, Ivonescimab
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
The researchers are doing this study to test the safety of ivonescimab given in combination with standard chemotherapy and stereotactic radiosurgery (SRS) in people with non-small cell lung cancer (NSCLC) that has spread to the…
- Trial name
- NCT07535463
- Testing
- Ivonescimab, Stereotactic Radiosurgery
- Where
- 7 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with…
- Trial name
- NCT07742956
- Testing
- ALK201 for injection, Ivonescimab Injection
- Volunteers
- 156 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.